After decades of failed treatments, a new drug called Lequmbi is offering some hope in the fight against Alzheimer's disease. "The medicine’s benefits are modest — it
slowed
cognitive decline by 27% in an 18-month clinical study run by the Japanese drug firm Eisai and its Cambridge partner Biogen — but hopes are high that it could mark a turning point in
Alzheimer’s research," per the
Boston Globe.
Read the whole story at Boston Globe »
